CytoCan

CytoCan, established in 2022 and headquartered in Hangzhou, China, is a biopharmaceutical company concentrated on developing treatments for challenging cancers. The firm operates on a foundational mission to create life-altering multispecific proteins to help patients combat cancer.

The core of CytoCan's operation is its proprietary modular platform, AbZed, designed to produce fusion proteins with multiple functions. This platform technology is analogous to building with LEGOs, comprising three distinct modules: affinity, connector, and cytokine. This structure allows for the creation of therapeutic proteins for new cancer targets by interchanging antibody fragments or ligands. Specifically, the technology aims to target immune cytokines directly to cancer cells, which helps in reducing the risk of systemic side effects.

The company's business strategy focuses on identifying unmet medical needs within oncology and designing targeted immune therapies. In February 2023, CytoCan secured CNY 10 million in a seed funding round. This financing was led by Forcefield Venture and included participation from XtalPi and Bopu Capital. The capital is intended to further optimize the AbZed platform, expand the product pipeline, and advance clinical studies. A key part of their strategy involves a collaboration with investor XtalPi to leverage artificial intelligence in conjunction with the AbZed platform for the joint development of new targeted immunotherapy drugs.

Keywords: biopharmaceutical, multispecific proteins, fusion proteins, AbZed platform, cancer therapy, immuno-oncology, targeted immune therapies, oncology, difficult-to-treat cancers, clinical studies, seed funding, XtalPi, Forcefield Venture, Bopu Capital, modular platform, affinity module, connector module, cytokine module, antibody fragments, systemic side effects